Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.5174
+0.0421 (8.86%)
Nov 18, 2025, 2:39 PM EST - Market open
Plus Therapeutics Revenue
Plus Therapeutics had revenue of $1.40M in the quarter ending September 30, 2025, a decrease of -4.05%. This brings the company's revenue in the last twelve months to $5.26M, down -8.16% year-over-year. In the year 2024, Plus Therapeutics had annual revenue of $5.82M with 18.54% growth.
Revenue (ttm)
$5.26M
Revenue Growth
-8.16%
P/S Ratio
4.10
Revenue / Employee
$250,381
Employees
21
Market Cap
71.11M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PSTV News
- 1 day ago - Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement - GlobeNewsWire
- 12 days ago - Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0 - GlobeNewsWire
- 18 days ago - Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory - GlobeNewsWire
- 2 months ago - Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire